# Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

> **NCT07107126** · PHASE1 · RECRUITING · sponsor: **Remedy Plan, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** RPT1G

## Key facts

- **NCT ID:** NCT07107126
- **Lead sponsor:** Remedy Plan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107126, "Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07107126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*